[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,642,620
  • Shares Outstanding, K 165,263
  • Annual Sales, $ 943,710 K
  • Annual Income, $ -381,390 K
  • EBIT $ -352 M
  • EBITDA $ -346 M
  • 60-Month Beta 0.38
  • Price/Sales 13.54
  • Price/Cash Flow N/A
  • Price/Book 26.01

Options Overview Details

View History
  • Implied Volatility 37.60% (+0.44%)
  • Historical Volatility 22.68%
  • IV Percentile 11%
  • IV Rank 17.24%
  • IV High 74.24% on 08/20/25
  • IV Low 29.96% on 05/07/26
  • Expected Move (DTE 19) 1.91 (2.50%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 317
  • Volume Avg (30-Day) 609
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 50,735
  • Open Int (30-Day) 49,601
  • Expected Range 74.59 to 78.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.08
  • Number of Estimates 8
  • High Estimate $-0.82
  • Low Estimate $-1.34
  • Prior Year $0.70
  • Growth Rate Est. (year over year) -254.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.93 +6.35%
on 05/18/26
79.19 -3.40%
on 05/14/26
+1.67 (+2.23%)
since 04/29/26
3-Month
68.90 +11.03%
on 03/24/26
82.75 -7.55%
on 03/02/26
-4.65 (-5.73%)
since 02/27/26
52-Week
32.00 +139.06%
on 05/29/25
86.74 -11.81%
on 02/05/26
+44.07 (+135.89%)
since 05/28/25

Most Recent Stories

More News
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

– Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – ...

IONS : 76.50 (-1.07%)
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts

Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference,...

IONS : 76.50 (-1.07%)
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals...

IONS : 76.50 (-1.07%)
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease

- Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - ...

IONS : 76.50 (-1.07%)
Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026....

IONS : 76.50 (-1.07%)
Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America Securities 2026...

IONS : 76.50 (-1.07%)
Ionis Pharmaceuticals: Q1 Earnings Snapshot

Ionis Pharmaceuticals: Q1 Earnings Snapshot

IONS : 76.50 (-1.07%)
Ionis reports first quarter 2026 financial results and highlights progress on key programs

- TRYNGOLZA ® (olezarsen) showed increasing demand in FCS driven by strong launch execution – - Olezarsen sNDA accepted by the FDA for Priority...

IONS : 76.50 (-1.07%)
Ionis Pharmaceuticals Approaches Its Earnings Call With Pipeline Momentum and Profitability Questions in Balance

Barchart Research What to Expect from IONS Earnings IONS Generated April 28, 2026 Current Price $71.78 EPS Estimate $$-0.89 Consensus Rating Moderate Buy Average Move 2.90% Ionis Pharmaceuticals Approaches...

IONS : 76.50 (-1.07%)
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

– Regulatory submission supported by Phase 3 B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B - ...

IONS : 76.50 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

See More

Key Turning Points

3rd Resistance Point 79.31
2nd Resistance Point 78.71
1st Resistance Point 77.60
Last Price 76.50
1st Support Level 75.89
2nd Support Level 75.29
3rd Support Level 74.18

See More

52-Week High 86.74
Last Price 76.50
Fibonacci 61.8% 65.83
Fibonacci 50% 59.37
Fibonacci 38.2% 52.91
52-Week Low 32.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.